• Maplight Therapeutics posted a net loss of USD 60.67 million for the quarter ended March 31, 2026, widening from USD 22.34 million a year earlier.
• Operating loss widened to USD 64.5 million as operating expenses more than doubled to USD 64.5 million.
• Research and development expense climbed to USD 53.68 million, driven by higher clinical trial costs of USD 24.82 million and employee-related expense of USD 15.99 million.
• General and administrative expense rose to USD 10.82 million on higher employee-related costs of USD 6.99 million.
• Cash, cash equivalents and investments totaled USD 395.2 million at March 31, 2026; ZEPHYR Phase 2 schizophrenia trial completed enrollment with 307 participants, with topline results expected by mid-August 2026, while IRIS Phase 2 ASD trial topline data are also expected by mid-August 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-224129), on May 14, 2026, and is solely responsible for the information contained therein.